{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:16:05Z","timestamp":1792880165246,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s00125-011-2398-8","type":"journal-article","created":{"date-parts":[[2011,12,21]],"date-time":"2011-12-21T10:52:10Z","timestamp":1324464730000},"page":"566-578","source":"Crossref","is-referenced-by-count":110,"title":["Reno-protective effects of renin\u2013angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"55","author":[{"given":"P.","family":"Vejakama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Thakkinstian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lertrattananon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ingsathit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ngarmukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,22]]},"reference":[{"key":"2398_CR1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1590\/S0104-42302004000300031","volume":"50","author":"RS Scheffel","year":"2004","unstructured":"Scheffel RS, Bortolanza D, Weber CS et al (2004) Prevalence of micro and macroangiopatic chronic complications and their risk factors in the care of outpatients with type 2 diabetes mellitus. Rev Assoc Med Bras 50:263\u2013267","journal-title":"Rev Assoc Med Bras"},{"key":"2398_CR2","first-page":"2026","volume":"148","author":"LJ Ubink-Veltmaat","year":"2004","unstructured":"Ubink-Veltmaat LJ, Bilo HJ, Meyboom-de Jong B (2004) Microalbuminuria in patients with type 2 diabetes mellitus in general practice. Ned Tijdschr Geneeskd 148:2026\u20132030","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2398_CR3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-004-1599-9","volume":"48","author":"AY Wu","year":"2005","unstructured":"Wu AY, Kong NC, de Leon FA et al (2005) An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 48:17\u201326","journal-title":"Diabetologia"},{"key":"2398_CR4","first-page":"465","volume":"44","author":"MA Gall","year":"1997","unstructured":"Gall MA (1997) Albuminuria in non-insulin-dependent diabetes mellitus. Prevalence, causes, and consequences. Dan Med Bull 44:465\u2013485","journal-title":"Dan Med Bull"},{"key":"2398_CR5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1191\/1358863x02vm412ra","volume":"7","author":"JP Garg","year":"2002","unstructured":"Garg JP, Bakris GL (2002) Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 7:35\u201343","journal-title":"Vasc Med"},{"key":"2398_CR6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000133312.96477.48","volume":"110","author":"K Klausen","year":"2004","unstructured":"Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32\u201335","journal-title":"Circulation"},{"key":"2398_CR7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archinte.1996.00440030080010","volume":"156","author":"M Ravid","year":"1996","unstructured":"Ravid M, Lang R, Rachmani R, Lishner M (1996) Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 156:286\u2013289","journal-title":"Arch Intern Med"},{"key":"2398_CR8","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0272-6386(00)70054-0","volume":"35","author":"P Ruggenenti","year":"2000","unstructured":"Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G (2000) Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35:1155\u20131165","journal-title":"Am J Kidney Dis"},{"key":"2398_CR9","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","volume":"366","author":"JP Casas","year":"2005","unstructured":"Casas JP, Chua W, Loukogeorgakis S et al (2005) Effect of inhibitors of the renin\u2013angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026\u20132033","journal-title":"Lancet"},{"key":"2398_CR10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","volume":"148","author":"R Kunz","year":"2008","unstructured":"Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30\u201348","journal-title":"Ann Intern Med"},{"key":"2398_CR11","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","volume":"329","author":"GF Strippoli","year":"2004","unstructured":"Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC (2004) Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 329:828","journal-title":"BMJ"},{"key":"2398_CR12","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002","journal-title":"BMJ"},{"key":"2398_CR13","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","volume":"61","author":"JL Peters","year":"2008","unstructured":"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2008) Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 61:991\u2013996","journal-title":"J Clin Epidemiol"},{"key":"2398_CR14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/1536867X0800800206","volume":"8","author":"TM Palmer","year":"2008","unstructured":"Palmer TM, Peter JL, Sutton AJ, Moreno SG (2008) Contour-enhanced funnel plots in meta-analysis. Stata J 8:242\u2013254","journal-title":"Stata J"},{"key":"2398_CR15","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23:3105\u20133124","journal-title":"Stat Med"},{"key":"2398_CR16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","volume":"326","author":"F Song","year":"2003","unstructured":"Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326:472","journal-title":"BMJ"},{"key":"2398_CR17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jclinepi.2007.06.006","volume":"61","author":"F Song","year":"2008","unstructured":"Song F, Harvey I, Lilford R (2008) Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 61:455\u2013463","journal-title":"J Clin Epidemiol"},{"key":"2398_CR18","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2337\/dc06-2493","volume":"30","author":"A Kashiwagi","year":"2007","unstructured":"Kashiwagi A (2007) Reduction of microalbuminuria in patients with type 2 diabetes. The Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 30:1581\u20131583","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"2398_CR19","first-page":"B54","volume":"23","author":"RO Estacio","year":"2000","unstructured":"Estacio RO, Jeffers BW, Gifford N, Schrier RW (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(Suppl 2):B54\u2013B64","journal-title":"Diabetes Care"},{"key":"2398_CR20","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/ki.1996.480","volume":"50","author":"GL Bakris","year":"1996","unstructured":"Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S (1996) Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641\u20131650","journal-title":"Kidney Int"},{"key":"2398_CR21","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1046\/j.1523-1755.2000.00879.x","volume":"57","author":"JC Chan","year":"2000","unstructured":"Chan JC, Ko GT, Leung DH et al (2000) Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 57:590\u2013600","journal-title":"Kidney Int"},{"key":"2398_CR22","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/01.HYP.21.6.786","volume":"21","author":"Y Lacourciere","year":"1993","unstructured":"Lacourciere Y, Nadeau A, Poirier L, Tancrede G (1993) Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 21:786\u2013794","journal-title":"Hypertension"},{"key":"2398_CR23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0168-8227(99)00114-X","volume":"47","author":"T Shiba","year":"2000","unstructured":"Shiba T, Inoue M, Tada H et al (2000) Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy. Diabetes Res Clin Pract 47:97\u2013104","journal-title":"Diabetes Res Clin Pract"},{"key":"2398_CR24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","author":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253\u2013259","journal-title":"Lancet"},{"key":"2398_CR25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-8227(01)00288-1","volume":"54","author":"S Baba","year":"2001","unstructured":"Baba S (2001) Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 54:191\u2013201","journal-title":"Diabetes Res Clin Pract"},{"key":"2398_CR26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713\u2013720","journal-title":"BMJ"},{"key":"2398_CR27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00228-005-0961-2","volume":"61","author":"R Fogari","year":"2005","unstructured":"Fogari R, Mugellini A, Zoppi A et al (2005) Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol 61:483\u2013490","journal-title":"Eur J Clin Pharmacol"},{"key":"2398_CR28","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0895-7061(02)03017-0","volume":"15","author":"R Fogari","year":"2002","unstructured":"Fogari R, Preti P, Zoppi A et al (2002) Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 15:1042\u20131049","journal-title":"Am J Hypertens"},{"key":"2398_CR29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bmj.37970.629537.0D","volume":"328","author":"M Marre","year":"2004","unstructured":"Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J (2004) Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 328:495","journal-title":"BMJ"},{"key":"2398_CR30","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/diabetes.46.7.1182","volume":"46","author":"FS Nielsen","year":"1997","unstructured":"Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH (1997) Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46:1182\u20131188","journal-title":"Diabetes"},{"key":"2398_CR31","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00004","volume":"128","author":"M Ravid","year":"1998","unstructured":"Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R (1998) Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128:982\u2013988","journal-title":"Ann Intern Med"},{"key":"2398_CR32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/0003-4819-118-8-199304150-00001","volume":"118","author":"M Ravid","year":"1993","unstructured":"Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M (1993) Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577\u2013581","journal-title":"Ann Intern Med"},{"key":"2398_CR33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851\u2013860","journal-title":"N Engl J Med"},{"key":"2398_CR34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861\u2013869","journal-title":"N Engl J Med"},{"issue":"11\u201320","key":"2398_CR35","first-page":"W13","volume":"151","author":"R Bilous","year":"2009","unstructured":"Bilous R, Chaturvedi N, Sjolie AK et al (2009) Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 151(11\u201320):W13\u2013W14","journal-title":"Ann Intern Med"},{"key":"2398_CR36","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1464-5491.2004.01316.x","volume":"21","author":"G Jerums","year":"2004","unstructured":"Jerums G, Allen TJ, Campbell DJ et al (2004) Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with type 2 diabetes and microalbuminuria. Diabet Med 21:1192\u20131199","journal-title":"Diabet Med"},{"key":"2398_CR37","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","volume":"372","author":"AK Sjolie","year":"2008","unstructured":"Sjolie AK, Klein R, Porta M et al (2008) Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 372:1385\u20131393","journal-title":"Lancet"},{"key":"2398_CR38","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/01.hjh.0000133733.32125.09","volume":"22","author":"M Marre","year":"2004","unstructured":"Marre M, Puig JG, Kokot F et al (2004) Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 22:1613\u20131622","journal-title":"J Hypertens"},{"key":"2398_CR39","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller H, Ito S, Izzo JL Jr et al (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364:907\u2013917","journal-title":"N Engl J Med"},{"key":"2398_CR40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.jhh.1000732","volume":"13","author":"R Fogari","year":"1999","unstructured":"Fogari R, Zoppi A, Corradi L et al (1999) Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 13:47\u201353","journal-title":"J Hum Hypertens"},{"key":"2398_CR41","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2337\/diacare.20.10.1576","volume":"20","author":"J Ahmad","year":"1997","unstructured":"Ahmad J, Siddiqui MA, Ahmad H (1997) Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20:1576\u20131581","journal-title":"Diabetes Care"},{"key":"2398_CR42","unstructured":"Lebovitz HE, Wiegmann TB, Cnaan A, et al. (1994) Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int (Suppl 45):S150\u2013S155"},{"key":"2398_CR43","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941\u20131951","journal-title":"N Engl J Med"},{"key":"2398_CR44","first-page":"S91","volume":"55","author":"L Mosconi","year":"1996","unstructured":"Mosconi L, Ruggenenti P, Perna A, Mecca G, Remuzzi G (1996) Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int Suppl 55:S91\u2013S93","journal-title":"Kidney Int Suppl"},{"key":"2398_CR45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1291\/hypres.30.325","volume":"30","author":"S Ogawa","year":"2007","unstructured":"Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S (2007) Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 30:325\u2013334","journal-title":"Hypertens Res"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00125-011-2398-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T01:15:17Z","timestamp":1561079717000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-011-2398-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,22]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["2398"],"URL":"https:\/\/doi.org\/10.1007\/s00125-011-2398-8","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,22]]}}}